Back to top
more

Geron (GERN)

(Delayed Data from NSDQ)

$4.14 USD

4.14
24,217,859

+0.35 (9.23%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $4.24 +0.10 (2.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern

Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.

    Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up

    Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.

      What's in the Cards for Geron (GERN) this Earnings Season?

      Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.

        Why Geron (GERN) Might Be a Diamond in the Rough

        Geron (GERN) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

          Geron Stock Up Almost 40% So Far This Year After '16 Decline

          Geron Corporation's (GERN) shares have risen 38.7% this year so far, outperforming the Zacks classified Medical - Biomedical and Genetics industry, which rose 5.6%. This comes after a decline of more than 57% in 2016.

            Jeffrey Hymen headshot

            5 Biomedical Stocks That Are Expected To Surge

            With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year. If you want to add some to your portfolio, check out these 5 biomedical stocks that are primed to skyrocket here.

              Here's Why Geron (GERN) is a Good Stock to Invest in Now

              Geron Corporation (GERN) is developing anti-cancer therapies based on telomerase inhibitors.

                The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics

                The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics

                  Tirthankar Chakraborty headshot

                  Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys

                  IBB surged 17% since Trump's win but is still down 23% from its all-time intraday high scaled in the July of 2015.

                    Mallinckrodt Initiates Amyotrophic Lateral Sclerosis Study

                    Mallinckrodt plc (MNK) announced that it has enrolled the first patient in its phase IIB study, PENNANT.

                      Omeros (OMER) Hits New 52-Week High on Positive FDA Decision

                      Omeros Corporation (OMER) shares hit a new 52-week high of $22.80 on Thursday before eventually closing at $22.15.

                        Geron (GERN) Up 3.1% Since Earnings Report: Can It Continue?

                        Geron (GERN) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.

                          Geron Corp (GERN) Worth a Look: Stock Adds 7% in Session

                          Geron Corporation (GERN) shares rose over 7% in the last trading session.

                            Geron (GERN) Q1 Loss In Line, Focus Remains on Imetelstat

                            Geron Corporation (GERN) reported a loss of 5 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate. In the year-ago quarter.

                              Geron (GERN) Q1 Earnings: What's in Store for the Stock?

                              Geron Corporation (GERN) is expected to report first-quarter 2017 results next week

                                Will Geron (GERN) Continue to Surge Higher?

                                As of late, it has definitely been a great time to be an investor in Geron Corporation (GERN).

                                  Top Ranked Momentum Stocks to Buy for April 18th

                                  Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 18th:

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback

                                    Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.

                                      Geron Stock Rises after Positive Interim Update on Imetelstat

                                      Shares of Geron Corporation (GERN) increased almost 20% on Monday after it provided a positive update on two late-stage studies for imetelstat, its lead pipeline candidate.

                                        Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat

                                        Geron Corporation (GERN) reported a loss of 5 cents per share in the fourth quarter of 2016, flat year over year but narrower than the Zacks Consensus Estimate of a loss of 6 cents.

                                          Drug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More

                                          With the curtains almost down on the Q4 earnings season, we believe this quarter has turned out to be a good one with growth on track to be the highest in the last two years.

                                            Geron (GERN) Q4 Earnings: What's in Store for the Stock?

                                            Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.